Verified Nov 2026
Other
·
Stockholm, Stockholm County
·
Since 2004
Calliditas Therapeutics is a specialty biopharmaceutical company headquartered in Stockholm, Sweden, founded in 2004. The company employs 200-500 people and generates estimated revenue of $100-250 million annually. It develops and commercializes therapies for rare renal and hepatic diseases, with TARPEYO® (budesonide) approved for primary IgA nephropathy and a pipeline including setanaxib for primary biliary cholangitis and Alport syndrome. As of September 2026, the company joined Asahi Kasei Therapeutics.
Calliditas Therapeutics at a glance
Revenue
$100-250M
Est. band
Employees
200-500
Founded
2004
Headquarters
Stockholm, Stockholm County
Industries
Automotive
Electric Vehicles
Medical
Overview
Calliditas Therapeutics is a specialty biopharmaceutical company headquartered in Stockholm, Sweden, founded in 2004. The company employs 200-500 people and generates estimated revenue of $100-250 million annually. It develops and commercializes therapies for rare renal and hepatic diseases, with TARPEYO® (budesonide) approved for primary IgA nephropathy and a pipeline including setanaxib for primary biliary cholangitis and Alport syndrome. As of September 2026, the company joined Asahi Kasei Therapeutics.
At a glance
Attribute | Detail |
|---|---|
Founded | 2004 |
Headquarters | Stockholm, Stockholm County |
Employees | 200-500 |
Revenue | $100-250M (estimated) |
What Calliditas Therapeutics makes
The company manufactures and supplies pharmaceutical products, with approved commercialized therapies including TARPEYO® and Kinpeygo® alongside clinical-stage candidates advancing through development.
Latest developments
2026-09-30 — Asahi Kasei unifies global drug business under ... (ibtimes.com)
2026-09-29 — We are excited to be joining Veloxis Pharmaceuticals and Aicuris Anti-infective Cures as part of Asahi Kasei Therapeutics! Follow us there to stay up to date on our progress to positively impact … | Calliditas Therapeutics (linkedin.com)
2026-03-30 — Calliditas Therapeutics AB to Present Exploratory Biomarker and Post-Hoc NefIgArd Analyses at the World Congress of Nephrology (prnewswire.com)
2026-03-30 — Calliditas therapeutics ab | Radio Compass News | PharmaCompass.com (pharmacompass.com)
2025-10-27 — Proud and pleased to announce that Olivia Gallegos joined Team Calliditas Therapeutics as Director Global Regulatory CMC. | Emelie Bäckvall (linkedin.com)
2025-04-16 — Welcome Calliditas Therapeutics • New Industrial partner in SweDeliver – SweDeliver – Uppsala University (uu.se)
Company details
Calliditas operates as a commercial-stage biopharmaceutical company focused on addressing unmet medical needs in nephrology and hepatology through drug discovery, clinical development, and manufacturing. Calliditas Therapeutics was founded in 2004, has an estimated 200-500 employees, and is headquartered in Stockholm, Stockholm County.
Frequently asked questions
What does Calliditas Therapeutics do?
Calliditas Therapeutics is a specialty biopharmaceutical company headquartered in Stockholm, Sweden, founded in 2004. The company employs 200-500 people and generates estimated revenue of $100-250 million annually. It develops and commercializes therapies for rare renal and hepatic diseases, with TARPEYO® (budesonide) approved for primary IgA nephropathy and a pipeline including setanaxib for primary biliary cholangitis and Alport syndrome. As of September 2026, the company joined Asahi Kasei Therapeutics.
Where is Calliditas Therapeutics headquartered?
Calliditas Therapeutics is headquartered in Stockholm, Stockholm County (26B Wallingatan, Stockholm, Stockholm County, 111 60).
When was Calliditas Therapeutics founded?
Calliditas Therapeutics was founded in 2004.
How big is Calliditas Therapeutics?
Calliditas Therapeutics has an estimated 200-500 employees, with revenue in the $100-250M range (estimated).
Related suppliers
Explore other suppliers in the LightSource directory:
Last verified Nov 2026. Is this your company? Request a correction.
Location & contact
Evaluating suppliers like these?
This profile is part of a public-data sample of the full LightSource directory. Book a demo to see the full LightSource marketplace and supplier discovery platform — 1M+ credible suppliers, with AI-run sourcing events.
